At Retrophin, our mission is to deliver life-changing therapies to people living with rare diseases, who have few, if any, treatment options.

Giving patients a chance, providing hope, is what drives us.

We are a fully-integrated biopharmaceutical company focused on advancing the development of our lead pipeline assets: fosmetpantotenate (RE-024) for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease.2These assets have pioneering potential, as fosmetpantotenate could be the first approved replacement therapy targeting the underlying cause of PKAN, and sparsentan could be the first FDA-approved pharmacological treatment for FSGS.

We are currently enrolling PKAN patients in our FOsmetpantotenate Replacement Therapy (FORT) Study, a Phase 3 clinical trial. Detailed information about this pivotal trial can be found at pkanfortstudy.com. We are also planning to initiate a pivotal Phase 3 trial for sparsentan in FSGS after receiving regulatory feedback during the second half of 2017. We are also advancing a liquid formulation of ursodeoxycholic acid for the treatment of a chronic liver disease called primary biliary cholangitis (PBC). We are pursuing a New Drug Application seeking a PBC indication from the FDA. If approved, we plan to make liquid ursodeoxycholic acid available to the subset of PBC patients who have difficulty swallowing.

These activities are complemented by our research exploring additional rare diseases. We are also  currently working with leaders in patient advocacy and public research on the development of a novel therapeutic for patients with NGLY1 deficiency.

Our focus on R&D is supported by revenues from our commercial products:Thiola®(tiopronin) tablets,Cholbam®(cholic acid) capsules, and Chenodal®(Chenodiol Tablets 250 mg). Since acquiring rights to Thiola, we have more than doubled access to this medication for patients with cystinuria and continue to work closely with the community to ensure all who are medically eligible for Thiola®have affordable access to it. Cholbam®is the first and only FDA-approved treatment for people with bile acid synthesis disorders and Zellweger spectrum disorders. Chenodal®is considered by the FDA to be medically necessary for the treatment of cerebrotendinous xanthomatosis (CTX), a rare, progressive and underdiagnosed lipid storage disease affecting many parts of the body.3,4

Our goal is to ensure that patients have an opportunity to achieve the best possible therapeutic outcomes, and we strive to meet their unique needs by investing in broader access to our medications. Our Total Care HUB®eases access to Thiola®, Cholbam®and Chenodal®by offering personalized and comprehensive support services – at no cost to patients, physicians or insurance companies. As part of this service, dedicated pharmacists and HUB counselors are available to answer product questions, and assist with insurance verification, reimbursement options and financial support.

We also work closely with the patient community to ensure that everyone who is medically eligible for our therapies has affordable access to them. We offer co-pay assistance and free medication to patients who qualify, as part of our patient assistance program. We also understand the challenges of receiving an accurate diagnosis and do our part by sponsoring free cholestatic genetic testing for qualified patients to help diagnose a variety of disorders.

Headquartered in San Diego with offices in Cambridge, MA and Dublin, Ireland, we are approximately 170 employees strong and structured to meet the unique needs of people living with rare diseases. Integrity, Accountability, Patient Focus, Teamwork, Scientific Excellence and Entrepreneurial Spirit are the values that guide our work each day and what we expect from one another.

Giving patients a chance, providing hope, is what drives us.

  1. Gregory, et al. GeneReviews. 2002.
  2. Middleton, et al. Nephrology Rounds 2007; 5(4).
  3. Data on file. San Diego, CA: Retrophin, Inc.
  4. Lorincz, et al. Arch Neurol 2005;62(9):1459-1463.